Italy's leading pediatric research hospital, specializing in rare diseases, immunotherapy, and clinical trial infrastructure for children across 30+ EU consortia.
Bambino Gesù is Italy's largest pediatric hospital and research center, based in Rome. They specialize in translational pediatric research — turning laboratory discoveries into treatments for children with rare diseases, cancer, immune disorders, and neurodevelopmental conditions. Their H2020 work centers on building clinical trial infrastructure for pediatric medicines, developing biomarkers for early diagnosis, and advancing cell and gene therapies (CAR-T, gene therapy for SCID) specifically adapted for young patients. They also contribute significantly to European rare disease data networks and personalized medicine initiatives.
Core contributor across RECOMB (gene therapy for SCID), ImmunAID (autoinflammatory disorders), EJP RD (rare disease data), EURE-CART and T2EVOLVE (CAR-T therapies), and RETHRIM (tissue regeneration in GvHD).
Major participant in c4c (EUR 4.2M — their largest grant), ID-EPTRI (paediatric translational infrastructure), INNODIA/INNODIA HARVEST (type 1 diabetes trials), and ChiLTERN (liver tumour network).
Active in ITCC-P4 (pediatric preclinical cancer platform), HARMONY/HARMONY PLUS (hematological malignancies), T2EVOLVE (CAR/TCR-engineered T cells), and CAPSTONE (antigen processing for cancer drugs).
Recurring theme across INNODIA (type 1 diabetes biomarkers), AIMS-2-TRIALS (autism biomarkers), PARENT (AI-based biomarkers for premature newborns), DIAMONDS (RNA molecular diagnosis), and CIRCULAR VISION (circular DNA diagnostics).
Recent projects PARENT (AI + neuroimaging), B1MG (genomic data standards/FAIR), PharmaLedger (machine-learning health data), and HARMONY PLUS (big data analytics) show growing digital health focus.
SHIPS (screening in preterm infants), RECAP preterm (long-term outcomes), and PARENT (early diagnosis of motor/cognitive impairments in premature newborns).
In the early period (2015–2018), Bambino Gesù focused on disease-specific clinical research — type 1 diabetes biobanks and trial networks (INNODIA), preterm infant screening (SHIPS), and building foundational pediatric infrastructure. From 2019 onward, their portfolio shifted markedly toward data-intensive and AI-driven approaches: FAIR data principles, microbiome analysis, personalized medicine, and artificial intelligence for diagnostics appear repeatedly in recent keywords. They also deepened their immunotherapy work, moving from early CAR-T research (EURE-CART) to more advanced translational platforms (T2EVOLVE, CAPSTONE).
Moving toward AI-powered diagnostics, FAIR data integration, and advanced immunotherapies — positioning themselves as a digital-first pediatric research hospital for the next funding cycle.
Bambino Gesù operates almost exclusively as a consortium partner (28 of 32 projects), contributing specialized pediatric clinical expertise to large European networks rather than leading them. With 552 unique partners across 43 countries, they are a highly connected hub in pediatric health research — the kind of partner that brings access to patient cohorts, clinical validation capabilities, and deep disease-specific knowledge. Their single coordinator role (INNERVATE) and three third-party participations suggest they prefer contributing clinical substance over managing administrative complexity.
Exceptionally well-networked with 552 unique consortium partners across 43 countries, making them one of the most connected pediatric institutions in H2020. Their network spans virtually all of Europe plus international collaborators, with strong ties to major university hospitals and rare disease consortia.
Bambino Gesù is one of Europe's very few dedicated pediatric hospitals with both deep clinical capacity and serious research output in H2020. This dual identity — active hospital treating thousands of children annually AND research center embedded in 30+ EU consortia — means they can offer something most academic partners cannot: direct access to pediatric patient populations for clinical validation. For any consortium needing pediatric clinical endpoints, rare disease cohorts, or child-specific regulatory expertise, they are a natural and proven partner.
